Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
华盛顿州温哥华和纽约，2025年1月2日（全球新闻稿） -- Absci公司（纳斯达克：ABSI），一家以数据为驱动的生成型人工智能药物创制公司，今日宣布将参加即将举行的第43届摩根大通医疗会议，地点在加利福尼亚州旧金山。
Absci management is scheduled to present on Wednesday, January 15th at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company's investor relations website at: investors.absci.com.
Absci管理层计划于1月15日（星期三）太平洋时间下午4:30（东部时间晚上7:30）进行演讲。感兴趣的各方可以通过公司的投资者关系网站访问演讲的现场直播和档案，网址为：investors.absci.com。
About Absci
关于Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci 是一家以数据为先的生成式人工智能药物创制公司，结合人工智能与可扩展的湿实验室技术，以更快地为患者创造更好的生物制品。我们的 综合药物创制 该平台释放了加速临床时间的潜力，并通过同时优化多个对开发和治疗益处都重要的药物特性来增加成功的概率。通过数据进行训练，利用人工智能进行创造，以及通过湿实验室进行验证，我们每周可以筛选数十亿个电芯，使我们能够在短短六周内从人工智能设计的候选者转变为湿实验室验证的候选者。Absci的总部位于华盛顿州温哥华，我们的人工智能研究实验室位于纽约市，创新中心位于瑞士楚格。请访问 并在LinkedIn上关注我们（@absci），X（推特）（@Abscibio), 和 YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投资者联系
亚历克斯·可汗
财务副总裁及投资者关系
investors@absci.com
Media Contact
press@absci.com
媒体联系
press@absci.com
